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a  b  s  t  r  a  c  t
Different  treatments  (surgery,  radiotherapy,  chemotherapy)  for gynaecological  cancers  may  cause  ovar-
ian  failure  or  increase  menopausal  symptoms.  There  is a widespread  reluctance  among  physicians  to
prescribe  hormone  replacement  therapy  (HRT)  to the  survivors  of gynaecological  cancer.  This  review
analyses  the  use  of  HRT  and  of  alternative  therapies  in  such  women.  Squamous  cervical  cancer  is not  estro-
gen dependent  and  thus  HRT  is not  contraindicated.  While  a cautious  approach  to  hormone-dependent
cancer  is  warranted,  for women  treated  for non-hormone-related  tumours  alternative  treatments  for
menopausal  symptoms  should  be given  due  consideration,  as any reluctance  to  prescribe  HRT  for them
has  neither  a  biological  nor  a clinical  basis.  In studies  of  HRT  for  survivors  of endometrial  and  ovarian
cancer,  for  instance,  no evidence  of  increased  risk  was  found,  although  no  definitive  conclusions  can  yet
be  formulated.  The  positive  effect  of HRT  on  quality  of  life  seems  to  outweigh  the  unfounded  suspicion  of
an increased  risk  of  recurrence  of  non-hormone-related  tumours.  Effective  non-hormonal  alternatives  for
vasomotor  symptoms  are  selective  serotonin  reuptake  inhibitors  and  selective  serotonin–norepinephrine
reuptake  inhibitors.
© 2015  Elsevier  Ireland  Ltd.  All  rights  reserved.
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1. Introduction
Due to advances in treatment, many women with gynaecolog-
ical cancers survive long after their primary surgery, and thus the
∗ Corresponding Author: Nicoletta Biglia, Obstetrics and Gynaecology, Mauriziano
Umberto I Hospital, Department of Surgical Sciences, University of Turin, Largo
Turati 62, 10128 Turin, Italy. Fax: +39 11 5082683.
E-mail address: nicoletta.biglia@unito.it (N. Biglia).
long-term consequences of estrogen deprivation may  affect their
quality of life (QoL).
Hot flushes (HFs) are the most frequently reported menopausal
symptoms, followed by insomnia, vaginal dryness and dyspareunia.
Systemic hormone replacement therapy (HRT) is the most effective
strategy in reducing menopausal symptoms in healthy women [1].
However, many physicians are reluctant to prescribe HRT to sur-
vivors of gynaecological cancers, regardless of exact tumor type
and disease stage, because of the lack of international guidelines
and the fear of medical litigation if a woman does go on to suffer a
recurrence while taking HRT [2].
http://dx.doi.org/10.1016/j.maturitas.2015.07.006
0378-5122/© 2015 Elsevier Ireland Ltd. All rights reserved.
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This article reviews clinical studies on the use HRT as well as




Endometrial cancer (EC) is an estrogen-dependent disease with
a favourable prognosis.  Thus, relieving menopausal symptoms is
important for maintaining a good QoL.
In a 13-year follow-up analysis of data from the Women’s Health
Initiative (WHI) [3], a reduced risk of EC in healthy women was
observed with combined estrogen–progestogen HRT (HR = 0.67,
95% CI 0.49–0.91). However, there was concern regarding HRT for
women previously treated for EC because of the fear that, even after
uterus removal, estrogens may  stimulate the growth of occult foci
of tumour cells.
The results of several small observational studies are reassur-
ing. In the study by Creasman,  47 patients with stage I EC used
conjugated estrogen by oral or vaginal routes for a median of 26
months. A lower recurrence rate (2.1% versus 14.9% of the placebo
group) and significant longer disease-free survival (DFS) and overall
survival (OS) were seen in the estrogen-treated group [4].
Lee [5] compared 44 stage I EC survivors using oral estrogens
with or without combined progestogen with 99 controls. No recur-
rence was observed in the HRT group, while 8% of patients in the
control group relapsed. However, selection bias was present since
HRT was prescribed only to low-risk patients (stage IA, IB grade 1
or 2) while 37% of controls had high-risk disease (stage IC grade 3).
In the study by Chapman [6], 62 patients with stage I or stage
II EC received HRT at a median time after surgery of 8 months and
61 similar patients did not receive HRT. No significant differences
in the recurrence rate or in OS were observed between the two
groups.
Suriano et al. [7] evaluated 75 women treated for stage I–III EC
who received HRT and 75 matched controls. In the HRT group a
lower recurrence rate (1%) was observed (14% in the control group);
moreover, HRT users had a significantly longer DFS.
Ahyan et al. [8] compared 50 patients receiving combined HRT
4–8 weeks after surgery and 52 matched controls, all treated for
stage I or stage II EC; no recurrence was observed in the HRT group,
whereas, one control experience recurrence.
The only prospective randomized controlled trial (RCT) was
from the Gynecologic Oncology Group (GOG) [9]. It involved 1236
women treated for EC randomized to estrogens alone or to placebo,
but it was closed prematurely after publication of the WHI  study
[10]. The majority of the enrolled patients had well differentiated
endometrioid EC; 91% had less than 50% myometrial invasion. No
significant difference in recurrence rate was observed, being very
low in both groups (2.1% in the 618HRT users versus 1.9% in the
placebo group).
All these studies were included in a recent meta-analysis [11]
that found no significant increased risk of recurrence in the 896 EC
survivors employing HRT compared with the 1079 controls.
As regards the type of HRT, there was a protective effect of com-
bined HRT (OR: 0.23; 95% CI: 0.08–0.66) on EC recurrence, whereas,
there was no such effect for estrogen-only HRT (OR: 0.35; 95% CI:
0.06–2.10). However, in the studies where a progestin was added
[5–7], with the exception of Ayhan et al. [8], only half of the HRT
users received it. For this reason, it remains unclear whether the
addition of progestins truly inhibits the stimulatory effect of estro-
gen on tumor cells.
The selection of healthier and younger women to begin HRT may
explain the protective effect of HRT on recurrence in EC survivors
seen in observational studies.
The minimum disease-free period before any HRT may be
started is still controversial. Since most recurrent ECs occur within
2 years of the initial diagnosis, some authors suggest that HRT
should not be started earlier than that [12]. However, in most stud-
ies patients received HRT sooner [4–7] and in the study by Ahyan
et al. [8] HRT was started immediately after surgery.
The available guidelines are conflicting, which undermines their
usefulness. For instance, the North America Menopause Society [1]
states that HRT is not recommended in women  with a history of
EC and suggests that progestogen alone should be considered for
the management of HFs, even if no long-term data are available.
In contrast, the National Comprehensive Cancer Network (NCCN)
Panel [13] states that estrogen-only HRT is a reasonable option for
patients who are at low risk of tumour recurrence, but that the exact
therapy should be individualised and discussed in detail with the
patient.
In conclusion, no definitive conclusions can be drawn, since no
long-term RCTs have been conducted. Patients should be coun-
seled on an individual basis and given information on the limited
evidence from the literature.
2.2. Uterine sarcomas
Among uterine sarcomas (carcinosarcomas, leiomyosarcomas,
adenosarcomas, endometrial stromal sarcomas), only endometrial
stromal sarcomas are considered to be estrogen dependent and HRT
should be avoided [2].
2.3. Cancer of the cervix
The role of HRT on cervical cancer (CC) depends on the tumour
histotype. Squamous CC is not considered to be estrogen respon-
sive and HRT does not seem to have a role in human papilloma
virus (HPV) replication. In the study by Ploch [14] on 120 women
treated for stage I or stage II CC (80 women treated with HRT and 40
non-treated), HRT produced no change in either OS or DFS. Cervical
adenocarcinomas account for 15% of all CCs and are dependent on
estrogen stimulation in the same way as EC.
2.4. Ovarian cancer
Most ovarian epithelial cancers (OC) appear in menopausal
women and disease prognosis is poor, with less than 30% of patients
with stage II–IV tumours alive 5 years after diagnosis. Nonetheless,
maintaining a good QoL is of course important.
Available data on HRT use in healthy women and OC risk are
conflicting. The WHI  trial did not find any increase in risk of OC for
HRT users [10]. However, a meta-analysis of 52 studies [15] found
an increased risk of OC in healthy HRT users.
Published studies on HRT use after OC treatment show no neg-
ative influence on disease prognosis and a great improvement in
QoL [16–19].
Eeles et al. [16] compared 78 OC survivors using HRT with
295 controls and found no differences in OS and DFS between
the two  groups. In the only RCT [17], 130 OC survivors were ran-
domly assigned to receive estrogen-only HRT or not 6–8 weeks
after surgery. No statistically significant differences in DFS and OS
were found between the two groups (32 recurrences in the HRT
group versus 41 recurrences in the control group). In a study by
Ursic-Vrscaj et al. [18], 24 OC survivors treated with HRT were
compared with 48 non-users and no detrimental effect on out-
come was observed in HRT users. The largest prospective study was
published by Mascarenas et al. [19], who analysed the OS of 649
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survivors of invasive OC and of 150 patients treated for borderline
ovarian tumor (BOT) according to HRT use before and after diag-
nosis. In women with invasive OC, there was no overall difference
in 5-year OS according to HRT use before diagnosis (HR 0.83, 95%
CI 0.65–1.08) but a better OS was observed for patients who  used
HRT after diagnosis (HR 0.57, 95% CI 5 0.42–0.78). For BOT patients,
no association was found between OS and HRT use before or after
diagnosis. BOTs are known to have a low potential for malignancy
and therefore carry a better prognosis than invasive OC.
Each OC histotype (high-grade serous, endometrioid, clear cell,
mucinous and low-grade serous carcinomas) is a distinct disease,
with different risk factors, hormone responsiveness and prognosis.
In particular, endometrioid OC is estrogen sensitive and residual
disease after treatment could be stimulated by HRT.
The overall consensus is that HRT should be considered in OC
patients who exhibit troublesome menopausal symptoms [2].
2.4.1. Alternatives to hormone treatment
For HFs, the most effective treatments are selective sero-
tonin reuptake inhibitors and selective serotonin–norepinephrine
reuptake inhibitors [20]; most of the relevant studies have been
performed on breast cancer survivors. Several recent studies
in healthy women have suggested that vaginal laser treatment
may  be effective for dyspareunia and vaginal atrophy, but no
RCTs are available. Bisphosphonates and the selective estrogen
receptor modulator (SERM) raloxifene may  be good alterna-
tives for bone protection. Lifestyle modification such as diet and
physical exercise can be considered for cardiovascular protec-
tion.
Research agenda
Consensus guidelines are needed. More RCTs on larger samples
are needed to draw definitive conclusions.
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